Pharmaceutical Technology

OCTOBER 5, 2023

Advanz Pharma has signed an agreement to licence Dimerix’s DMX-200 for marketing in the UK, Australia and New Zealand among others.

Licensing 130

Licensing Licensing Drugs Marketing 130

Bio Pharma Dive

DECEMBER 14, 2021

Fitusiran, which Sanofi licensed from Alnylam, could finally get to market after trial delays and safety concerns slowed its progress. But gene therapies and other new medicines might provide competition.

Gene Therapy 325

Gene Therapy Licensing Licensing Gene 325

Pharmaceutical Technology

JANUARY 23, 2023

Takeda has signed an exclusive licence agreement with HUTCHMED (China) and its subsidiary HUTCHMED to develop and market the latter’s fruquintinib. The China National Medical Products Administration (NMPA) approved fruquintinib for marketing in September 2018. The submission is planned to be completed in the first half of this year.

Licensing 130

Licensing Licensing Sales Medicine 130

Pharmaceutical Technology

JULY 28, 2022

Melinta Therapeutics has signed a licence agreement with Cidara Therapeutics to facilitate a strategic collaboration for marketing the latter’s rezafungin in the US. The collaboration comes after Cidara filed a New Drug Application (NDA) for rezafungin to treat candidemia and invasive candidiasis.

Licensing 147

Licensing Licensing Clinical Trials Clinical Trials 147

BioPharma Reporter

OCTOBER 31, 2023

The French biotech company Vect-Horus has licensed its technology to the Danish big pharma Novo Nordisk to deliver drug cargoes to undisclosed disease targets in three programs.

Licensing 59

Licensing Licensing Drug Delivery Drugs 59

Pharmaceutical Technology

JULY 19, 2023

The agreement covers licensing rights in North America for Duchenne muscular dystrophy and other future indications.

Licensing 130

Licensing Licensing Marketing Drugs 130

Bio Pharma Dive

FEBRUARY 14, 2024

The biotech is planning to dissolve less than four years after launching with plans to license drugs and market them in China and other Asian countries.

Licensing 173

Licensing Licensing Marketing Drugs 173

Pharmaceutical Technology

OCTOBER 23, 2023

On 2 October, Eli Lilly announced that the US Food and Drug Administration (FDA) had issued a complete response letter (CRL) regarding the biologic license application (BLA) for its anti-interleukin (IL)-13 biologic lebrikizumab for the treatment of adults and adolescents (12 and older) with moderate-to-severe atopic dermatitis (AD).

Manufacturing 130

Manufacturing Marketing Licensing Licensing 130

BioPharma Reporter

MAY 20, 2024

CRISPR licensing company ERS Genomics and drug discovery firm IRBM have entered into a non-exclusive CRISPR/Cas9 license agreement.

Licensing 52

Licensing Licensing Genome Genomics 52

BioPharma Reporter

APRIL 2, 2024

Ipsen is expanding its oncology pipeline by securing the global licensing rights to an antibody-drug conjugate (ADC) for solid tumors from Sutro Biopharma, its first drug in the category.

Licensing 52

Licensing Licensing Antibody Drugs 52

Pharmaceutical Technology

APRIL 27, 2023

The European Commission’s (EC) long-anticipated pharma reform plans in the European Union have finally been unveiled , indicating a focus on improving access to medicines across the bloc while cutting down on market exclusivity. Outside of these steps, the reform targets drug shortages and pharma industry’s environmental impact.

Marketing 264

Marketing Medicine Production Clinical Trials 264

Roots Analysis

AUGUST 1, 2024

GLP-1 receptor agonist market have captured the attention of both large and small pharmaceutical companies, for more than a decade. However, after a decade-long dribble of GLP-1 drugs and the recent approval of obesity drugs, the domain has gained significant attention.

Marketing 52

Marketing Insulin Drugs Development 52

Bio Pharma Dive

MARCH 13, 2023

The deal builds on a licensing agreement between Sanofi and Provention to market the first-of-its-kind treatment, called Tzield and approved to slow the disease’s progression.

Licensing 130

Licensing Licensing Drugs Marketing 130

Pharmaceutical Technology

MAY 3, 2023

Aurinia Pharmaceuticals has received marketing authorisation from the Swiss Agency for Therapeutic Products (Swissmedic) for Lupkynis (voclosporin), along with a background immunosuppressive therapy. Lupkynis has also received orphan drug designation in Switzerland. This promotes podocyte stability in the kidneys.

Marketing 130

Marketing Licensing Licensing Production 130

Fossil Remedies

OCTOBER 16, 2022

In a pharma business, you have a distribution network like a pharma manufacturing company, pharma marketing company, C&F agents, wholesalers/distributors/stockiest, retailers, and pharmacies. To launch the best PCD pharma franchise company, you will have to acquire the necessary licenses from authorities. Wholesale Drug License.

Licensing 52

Licensing Licensing Pharma Companies Manufacturing 52

pharmaphorum

SEPTEMBER 27, 2022

While a rumoured takeover by Merck & Co has yet to materialise, Seagen is getting on with its own business development, including a just-agreed licensing deal for a cancer immunotherapy developed by Dutch biotech Lava Therapeutics. The post Lava fires up a $700m cancer licensing deal with Seagen appeared first on.

Licensing 111

Licensing Licensing FDA Approval Clinical Trials 111

Pharmaceutical Technology

MAY 24, 2023

Y-mAbs Therapeutics has received marketing authorisation for Danyelza (naxitamab-gqgk) 40mg/10mL injection from the Brazilian Health Regulatory Agency, Agência Nacional de Vigilância Sanitária, to treat high-risk neuroblastoma. The therapy is given three times a week and repeated every four weeks.

Marketing 130

Marketing Licensing Licensing Antibody 130

BioPharma Reporter

SEPTEMBER 25, 2023

MC2 Therapeutics has acquired the exclusive licensing rights for Regranionâs RGRN-305, a new treatment for hidradenitis suppurativa (HS).

Licensing 52

Licensing Licensing Drugs Regulation 52

Bio Pharma Dive

APRIL 13, 2022

Antares Pharma's auto-injector technology is of particular interest to Halozyme, which believes that the various markets to which it could be applied represent billions of dollars in potential sales.

Drug Delivery 143

Drug Delivery Licensing Licensing Sales 143

BioPharma Reporter

OCTOBER 26, 2023

The biopharmaceutical industry witnessed a 400% growth in total deal value of antibody-drug conjugate (ADC) licensing agreements from 2017-2022 and reached a peak of $16.6 billion in 2022, reveals data and analytics company GlobalData.

Licensing 59

Licensing Licensing Antibody Drugs 59

pharmaphorum

JANUARY 9, 2023

Swiss biotech Stalicla has continued to diversify its pipeline from a focus on autism therapies with a deal to license Novartis’ mavoglurant, in clinical trials for cocaine use disorder (CUD) as well as neurodevelopmental disorders (NDD). The market potential of the CUD and NDD indications alone could top 2 billion euros ($2.12

Licensing 59

Licensing Licensing Trials Clinical Trials 59

BioTech 365

JUNE 9, 2021

World Pancreatic Cancer Market Spotlight 2021-2031: Key Marketed and Pipeline Drugs, Events, Clinical Trials, Regulations, Disease Prevalence, Licensing and Acquisition, Revenue – ResearchAndMarkets.com World Pancreatic Cancer Market Spotlight 2021-2031: Key Marketed and Pipeline Drugs, Events, Clinical Trials, Regulations, Disease Prevalence, (..)

Clinical Trials 40

Clinical Trials Clinical Trials Regulation Licensing 40

BioTech 365

JUNE 9, 2021

Global Osteoarthritis and Osteoarthritis Pain Market 2021-2031: Key Marketed and Pipeline Drugs, Events, Clinical Trials, Regulations, Disease Prevalence, Licensing and Acquisition, Revenue – ResearchAndMarkets.com Global Osteoarthritis and Osteoarthritis Pain Market 2021-2031: Key Marketed and Pipeline Drugs, Events, Clinical Trials, Regulations, (..)

Clinical Trials 40

Clinical Trials Clinical Trials Regulation Licensing 40

XTalks

OCTOBER 22, 2024

Astellas Pharma has won approval from the US Food and Drug Administration (FDA) for Vyloy (zolbetuximab) as a first-line treatment for adults with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. The drug is specifically indicated for patients whose tumors are HER2-negative and express claudin 18.2

FDA Approval 90

FDA Approval Drugs Licensing Licensing 90

Pharmaceutical Technology

DECEMBER 26, 2022

LegoChem Biosciences and Amgen have signed a multi-target research collaboration and license agreement to develop antibody-drug conjugates (ADC). Till date, the company has signed a total of 12 ADC licensing deals, worth more than $5bn.

Antibody 130

Antibody Development Drugs Licensing 130

BioTech 365

JANUARY 27, 2022

Attention Deficit Hyperactivity Disorder (ADHD) Market Spotlight Report 2021: 10-year Disease Prevalence Forecast, and Licensing and Acquisition Deals, Drug-specific Revenue Forecasts – ResearchAndMarkets.com Attention Deficit Hyperactivity Disorder (ADHD) Market Spotlight Report 2021: 10-year Disease Prevalence Forecast, and Licensing and Acquisition (..)

Licensing 40

Licensing Licensing Marketing Drugs 40

BioTech 365

JANUARY 27, 2022

Systemic Hypertension Market Spotlight Report 2021: 10-Year Disease Prevalence Forecast, Clinical Trials, Regulatory Events, Licensing and Acquisitions, and Drug-specific Revenue Forecasts – ResearchAndMarkets.com Systemic Hypertension Market Spotlight Report 2021: 10-Year Disease Prevalence Forecast, Clinical Trials, Regulatory Events, Licensing (..)

Clinical Trials 40

Clinical Trials Clinical Trials Licensing Licensing 40

BioTech 365

JANUARY 27, 2022

Glioblastoma (GBM) Market Spotlight Report 2021: 10-Year Disease Prevalence Forecast, Clinical Trials, Regulatory Events, Licensing and Acquisitions, and Drug-specific Revenue Forecasts – ResearchAndMarkets.com Glioblastoma (GBM) Market Spotlight Report 2021: 10-Year Disease Prevalence Forecast, Clinical Trials, Regulatory Events, Licensing and (..)

Clinical Trials 40

Clinical Trials Clinical Trials Licensing Licensing 40

pharmaphorum

NOVEMBER 23, 2021

Sanofi has bolstered its push into mRNA-based therapies with a new licensing deal – but not as might be expected with some up-and-coming biotech company. Sanofi is the first pharma company to partner with Baidu on its LinearDesign AI platform, which has been developed specifically to optimise the sequence of mRNA-based vaccines and drugs.

Licensing 105

Licensing Licensing Vaccination Vaccine 105

Pharmaceutical Technology

JUNE 5, 2023

Pint-Pharma will obtain and maintain all marketing authorisations and will commercialise BESREMi in the region. It holds orphan drug designation in the US to treat PV. In 2019, the European Medicines Agency approved the therapy, which has also been licensed in Japan, Taiwan and South Korea.

Marketing 130

Marketing Licensing Licensing Sales 130

BioTech 365

JANUARY 27, 2022

Atrial Fibrillation (AF) Market Spotlight Report 2021: 10-Year Disease Prevalence Forecast, Clinical Trials, Regulatory Events, Licensing and Acquisitions, and Drug-Specific Revenue Forecasts – ResearchAndMarkets.com Atrial Fibrillation (AF) Market Spotlight Report 2021: 10-Year Disease Prevalence Forecast, Clinical Trials, Regulatory Events, (..)

Clinical Trials 40

Clinical Trials Clinical Trials Licensing Licensing 40

BioTech 365

JANUARY 27, 2022

Systemic Lupus Erythematosus (SLE)Market Spotlight Report 2021: 10-Year Disease Prevalence Forecast, Clinical Trials, Regulatory Events, Licensing and Acquisitions, and Drug-specific Revenue Forecasts – ResearchAndMarkets.com Systemic Lupus Erythematosus (SLE)Market Spotlight Report 2021: 10-Year Disease Prevalence Forecast, Clinical Trials, (..)

Clinical Trials 40

Clinical Trials Clinical Trials Licensing Licensing 40

pharmaphorum

DECEMBER 7, 2021

AstraZeneca has snapped up another Ionis-discovered drug for its pipeline, this time phase 3 candidate eplontersen for the disease transthyretin amyloidosis (ATTR). billion in milestones depending on sales levels if the antisense-based drug reaches the market.

Licensing 59

Licensing Licensing Drugs Marketing 59

Pharmaceutical Technology

MAY 10, 2023

Gilead Sciences has emerged victorious in a legal battle with the US government over patents surrounding the HIV pre-exposure prophylaxis (PrEP) drugs Descovy and Truvada following a federal jury’s verdict on May 9. Gilead markets both Truvada and its successor Descovy.

Drugs 264

Drugs FDA Approval Containment Licensing 264

BioPharma Reporter

DECEMBER 6, 2021

Australiaâs Noxopharm has in-licensed novel RNA tech developed by Hudson Institute of Medical Research: focusing on RNA drug discovery and mRNA vaccine manufacture via Noxopharmâs subsidiary Pharmorage.

RNA 52

RNA Licensing Licensing Vaccination 52

Cloudbyz

AUGUST 2, 2022

Premarketing drug studies vs Post- Marketing research. Premarketing drug studies consist of phase I-III trials, and are represented by pharmacokinetic and pharmacodynamic studies, dose ranging studies, and Randomized Controlled Trials (RCTs). Approximately only 20 % of the drugs that enter phase I are approved for marketing.

Marketing 97

Marketing Research Clinical Trials Clinical Trials 97

BioPharma Reporter

JANUARY 6, 2023

Synaffix, a Netherlands based company providing clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), has signed off on two new licensing deals this week.

Licensing 52

Licensing Licensing Antibody Development 52